Targets | Trials (n) | % |
|---|
Multi-RTK | 40 | 31.3 |
VEGFR | 17 | 13.3 |
mTOR | 12 | 9.4 |
HDAC | 9 | 7.0 |
Combination targets | 8 | 6.3 |
CDK | 6 | 4.7 |
IGF-1R | 5 | 3.9 |
PDGFR | 5 | 3.9 |
Hedgehog | 3 | 2.3 |
AKT | 2 | 1.6 |
CD105 | 2 | 1.6 |
EGFR | 2 | 1.6 |
HER2 | 2 | 1.6 |
Hypoxic region | 2 | 1.6 |
MET | 2 | 1.6 |
26S proteasome | 1 | <1 |
Aurora A | 1 | <1 |
CRM1 | 1 | <1 |
DR5 | 1 | <1 |
Endoglin | 1 | <1 |
Endosialin/TEM1 | 1 | <1 |
G6PD | 1 | <1 |
PPAR-γ | 1 | <1 |
SRC | 1 | <1 |
Tie2 | 1 | <1 |
β-receptor | 1 | <1 |
- The different targets of 128 registered clinical trials. RTK, receptor tyrosine kinase; VEGFR, vascular endothelial growth factor receptor; HDAC, histone deacetylase; CDK, cyclin-dependent kinase; IGF-1R, insulin-like growth factor 1 receptor; PDGFR, platelet-derived growth factor receptor; AKT, protein kinase B; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; MET, a receptor tyrosine kinase that is produced as a single-chain precursor; CRM1, chromosomal maintenance 1; DR5, death receptor-5; G6PD, glucose-6-phosphate dehydrogenase; PPAR-γ, peroxisome proliferator-activated receptors; SRC, proto-oncogene tyrosine-protein kinase; Tie2, tyrosine kinase with immunoglobulin-like and EGF-like domains 1
